title: Thrombospondin-1-Derived Peptide RFYVVMWK Improves the Adhesive Phenotype of CD34+Cells From Atherosclerotic Patients With Type 2 Diabetes.
abstract: CD34+ progenitor cells are growing in use for vascular repair. However, in diabetic individuals with cardiovascular diseases, these cells have dysfunctional engraftment capabilities, which compromise their use for autologous cell therapy. The thrombospondin-1-derived peptide RFYVVMWK has previously been reported to stimulate cell adhesiveness through CD47 and integrin activation pathways. Our aim was to test whether RFYVVMWK preconditioning could modulate CD34+ cell phenotype and enhance its proadhesive properties in diabetic patients. Peripheral blood mononuclear CD34+ cells isolated from 40 atherosclerotic patients with type 2 diabetes (T2D; n = 20) or without (non-T2D; n = 20) were preconditioned with 30 μM RFYVVMWK or truncated peptide RFYVVM. CD34+ cell adhesion was assessed on a vitronectin-collagen matrix and on TNF-α or IL-1β-stimulated HUVEC monolayers. Adhesion receptors, platelet/CD34+ cell conjugates, and cell viability were analyzed by flow cytometry and confocal microscopy. RFYVVMWK increased the adhesion of T2D CD34+ cells by eightfold to the vitronectin-collagen matrix (p < 0.001) corresponding to a threefold increase compared to unstimulated non-T2D CD34+ cells. The peptide induced the formation of platelet/CD34+ conjugates and increased the expression of TSP-1, CD29, CD51/CD61, and CD62P in both T2D and non-T2D cells. However, RFYVVMWK treatment did not affect the viability/apoptosis of CD34+ progenitor cells. In conclusion, priming CD34+ cells with RFYVVMWK may enhance their vascular engraftment during autologous proangiogenic cell therapy.
authors.forename: Sylvie
authors.initials: S
authors.lastname: Cointe
authors.forename: Éric
authors.initials: É
authors.lastname: Rhéaume
authors.forename: Catherine
authors.initials: C
authors.lastname: Martel
authors.forename: Olivier
authors.initials: O
authors.lastname: Blanc-Brude
authors.forename: Evemie
authors.initials: E
authors.lastname: Dubé
authors.forename: Florence
authors.initials: F
authors.lastname: Sabatier
authors.forename: Françoise
authors.initials: F
authors.lastname: Dignat-George
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Tardif
authors.forename: Arnaud
authors.initials: A
authors.lastname: Bonnefoy
mesh_terms: D054058:Acute Coronary Syndrome / Q000276:immunology / Q000378:metabolism; D000368:Aged; D060050:Angina, Stable / Q000276:immunology / Q000378:metabolism; D018952:Antigens, CD34 / Q000378:metabolism*; D050197:Atherosclerosis / Q000276:immunology* / Q000378:metabolism*; D002448:Cell Adhesion / Q000502:physiology; D002478:Cells, Cultured; D003094:Collagen / Q000378:metabolism; D003324:Coronary Artery Disease / Q000276:immunology / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000276:immunology* / Q000378:metabolism; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000737:chemistry* / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000737:chemistry / Q000494:pharmacology; D019700:Thrombospondin 1 / Q000737:chemistry*; D019096:Vitronectin / Q000378:metabolism
chemical_list: D018952:Antigens, CD34; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019700:Thrombospondin 1; D019096:Vitronectin; D003094:Collagen